BiomX Inc.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors.

BiomX Announces the Appointments of Jason M. Marks and Michael E.

BiomX (NYSEMKT: PHGE ) stock is on the rise Friday as investors prepare for the clinical-stage company to release its latest earnings report on Monday. That means investors will want to check in on the company early as it plans to release its Q1 report before markets open.

Why Is BiomX (PHGE) Stock Up 10% Today?

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m. ET, to report first quarter 2023 financial results and provide business updates.

BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its recently announced $7.5 million private placement (“PIPE”) investment.

BiomX Announces Second Closing of $7.5 Million Private Placement

BiomX Inc. (NYSE:PHGE ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Operator Good morning, and welcome to the BiomX Full Year 2022 Financial Results and Corporate Update Conference Call.

BiomX Inc. (PHGE) Q4 2022 Earnings Call Transcript

BiomX (NYSEMKT: PHGE ) stock is rising on Wednesday following the release of the company's earnings report for the fourth quarter of 2022. Starting off that earnings report is the company's net loss of $28.3 million, or 95 cents per share.

Why Is BiomX (PHGE) Stock Up 8% Today?

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”)

BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 29th, 2023, at 8:00 a.m. ET, to report fourth quarter and full year 2022 financial results and provide business updates.

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

BiomX (NYSEMKT: PHGE ) stock is taking a beating on Wednesday after the clinical-stage microbiome company revealed details of a new private placement. According to a news release, BiomX has entered into a securities purchase agreement with select institutional and individual investors.

Why Is BiomX (PHGE) Stock Down 11% Today?

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement (“SPA”) with a select group of institutional and individual investors (the “Investors”), including existing investors OrbiMed and the Cystic Fibrosis Foundation, to issue and sell an aggregate of 30,608,163 shares of its common stock (or common stock equivalents, the “Securities”) at a price of $0.245 per share, which is based on a volume-weighted average price (VWAP) of BiomX common stock over the past 60 days, through a private investment in public equity (“PIPE”) financing. BiomX anticipates the gross proceeds from the PIPE to be approximately $7.5 million, before deducting offering expenses. The financing is expected to close in two parts. The first closing, which covers 5,975,918 Securities for gross proceeds of $1.5 million, is anticipated to occur promptly, subject to the satisfaction of customary closing conditions. The second closing for the remaining Securities, which is contingent upon approval of the issuance of the additional Securities under the SPA by the Company's stockholders in accordance with NYSE American rules, is expected to take place in the second quarter of 2023.

BiomX Announces $7.5 Million Private Placement

BX004 therapy safe and well - tolerated across all patients and dose levels

BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

BiomX, Inc. (NYSE:PHGE ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Mike Higgins - Ladenburg Thalmann Richard Miller - Cantor Fitzgerald Operator Good morning, and welcome to the BiomX Third Quarter 2022 Financial Results and Corporate Update Conference Call.

BiomX, Inc. (PHGE) Q3 2022 Earnings Call Transcript

Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates.

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.   H.C Wainwright Global Investment Conference – September 12-14, 2022     Date & Time: Mond

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

BiomX Inc. (NYSE:PHGE ) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Marina Wolfson - Chief Financial Officer Jonathan Solomon - Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kristen Kluska – Cantor Fitzgerald Michael Higgins - Ladenburg Thalmann Keay Nakae - Chardan Operator Good morning.

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2022 Results - Earnings Call Transcript

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022. “It has been an eventful quarter for the Company. We enrolled our first patients in our BX004 cystic fibrosis program, expanded our partnerin

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled “Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation” in the journal, Cell. The research was conducted across several organizat

BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange (the “TASE”). Based upon a review of the recent trading volume of BiomX's common stock on the TASE and the costs associated with m

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc (NYSE: PHGE) has announced a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD).  BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific.

Why BiomX Shares Are Trading Higher Today?

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (“IBD”). BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifyi

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

BRANFORD, Conn. and NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the dosing of the first two patients in the Company's Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with cystic fibrosis (“CF”). “We are pleased to reach this important clinical m

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc (NYSE: PHGE) announced a corporate restructuring plan to focus its resources and extend the cash runway. The company had $55.7 million in cash, cash equivalents, short-term deposits, and a $15 million debt facility as of March 31.

News for BiomX Inc. Stock (PHGE)